Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Immunic (Nasdaq: IMUX) notified investors that it has regained compliance with Nasdaq's minimum bid price rule.
According to the company, the closing bid price remained at or above $1.00 per share for at least 20 consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2) on March 26, 2026, and the Listing Qualifications matter was closed.
AI-generated analysis. Not financial advice.
Positive
- Regained Nasdaq minimum bid price compliance on March 26, 2026
- Listing matter officially closed by Nasdaq
Negative
- Previously failed to meet Nasdaq minimum bid price requirement, risking delisting
News Market Reaction – IMUX
On the day this news was published, IMUX gained 3.60%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.3% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $144.82M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMUX gained 7.77% while peers showed mixed moves: ABOS +7.53%, ATRA +7.5%, CRVO +7.65%, IGMS -2.31%. Momentum scanners only flagged IRD moving down, indicating today’s strength in IMUX appears stock-specific rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Board appointment | Positive | +7.8% | Appointment of experienced biopharma executive Jon Congleton to the board. |
| Mar 10 | IP / patent news | Positive | +3.2% | European patent grant protecting vidofludimus calcium dosing regimens into the 2030s. |
| Mar 03 | Investor conferences | Positive | +0.9% | Participation in healthcare and CNS investor conferences with leadership presentations. |
| Feb 26 | Earnings & update | Positive | +4.1% | Year-end 2025 results with financing and guidance on Phase 3 timelines and cash runway. |
| Feb 17 | Private placement | Negative | -4.4% | Oversubscribed private placement raising $200M upfront via pre-funded warrants. |
Over recent months, IMUX news has generally been followed by price moves in the same direction as the perceived news tone, with financing-related dilution being the main negative outlier.
Across the last five news events since Feb 17, 2026, Immunic has reported an oversubscribed private placement, year-end 2025 financials with extended cash runway, new European patent protection into the late 2030s, investor conference participation, and a seasoned director appointment. Most updates had positive or constructive implications and saw positive next-day reactions, except the dilutive private placement, which drew a negative response. Today’s Nasdaq compliance notice fits into this pattern of de-risking corporate milestones.
Market Pulse Summary
This announcement confirms that IMUX regained compliance with Nasdaq’s $1.00 minimum bid price after maintaining that level for at least 20 consecutive trading days, closing out a prior deficiency notice. It removes an immediate delisting overhang tied to the Nasdaq Capital Market. In context of recent financings, governance changes, and patent wins, this reduces regulatory risk but does not address underlying clinical, financing, or commercialization execution, which remain key factors to monitor alongside future Phase 3 data catalysts.
Key Terms
minimum bid price requirement regulatory
the nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
According to the Notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the Company's common stock was at
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302730954.html
SOURCE Immunic, Inc.